ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
1-Year Est. Return
26.77%
1 Year Est. Return
+26.77%
AUM
$616M
AUM Growth
+$96.2M
(+19%)
Holding
239
Top Buys
| 1 | +$52.1M | |
| 2 | +$20.5M | |
| 3 | +$14M | |
| 4 |
CytomX Therapeutics
CTMX
|
+$6.89M |
| 5 |
ABVX
Abivax
ABVX
|
+$6.59M |
Top Sells
| 1 | +$17.4M | |
| 2 | +$8.63M | |
| 3 | +$6.94M | |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$6.34M |
| 5 |
AVR
Anteris Technologies
AVR
|
+$4.35M |
Sector Composition
| 1 | Healthcare | 83.61% |
| 2 | Financials | 2.95% |
| 3 | Consumer Discretionary | 0% |
| 4 | Industrials | 0% |
| 5 | Utilities | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Keros Therapeutics
KROS
$418M
| $71.9M | 11.03% |
5,389,264
+3,902,803
|
|
||
2
Protagonist Therapeutics
PTGX
$4.75B
| $52.4M | 8.04% |
948,069
+8,400
|
|
||
3
Alpha Architect 1-3 Month Box ETF
BOXX
$8.11B
| $38M | 5.83% |
337,125
|
|
||
4
Zai Lab
ZLAB
$3.13B
| $29.7M | 4.56% |
850,437
-90,421
|
|
||
|
ABVX
5
Abivax
ABVX
$7.14B
| $23.5M | 3.6% |
3,071,340
+861,321
|
|
||
6
Roivant Sciences
ROIV
$11.7B
| $21.9M | 3.35% |
1,940,797
-1,542,607
|
|
||
7
Prothena Corp
PRTA
$528M
| $20.5M | 3.14% |
+3,375,009
|
|
||
8
Cytokinetics
CYTK
$6.98B
| $19.2M | 2.95% |
582,147
+191,418
|
|
||
9
SPDR S&P 500 ETF Trust
SPY
$657B
| $14M | 2.15% |
+22,684
|
|
||
10
CG Oncology
CGON
$3.14B
| $13.6M | 2.09% |
523,216
+222,082
|
|
||
11
SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$42B
| $12.4M | 1.91% |
135,585
|
|
||
12
BridgeBio Pharma
BBIO
$10.5B
| $11.2M | 1.72% |
259,659
-79,976
|
|
||
13
Inhibikase Therapeutics
IKT
$121M
| $9.99M | 1.53% |
5,122,105
|
|
||
|
SEPN
14
Septerna Inc
SEPN
$960M
| $8.96M | 1.37% |
847,227
+126,379
|
|
||
15
Arbutus Biopharma
ABUS
$847M
| $8.73M | 1.34% |
2,825,773
+946,659
|
|
||
16
89bio
ETNB
$2.19B
| $8.6M | 1.32% |
875,983
+71,763
|
|
||
17
Immunovant
IMVT
$2.99B
| $8.56M | 1.31% |
535,066
-433,800
|
|
||
18
Savara
SVRA
$619M
| $8.21M | 1.26% |
3,600,670
+2,240,379
|
|
||
19
Xenon Pharmaceuticals
XENE
$3.21B
| $8.12M | 1.25% |
259,503
+131,955
|
|
||
|
BIOA
20
BioAge Labs
BIOA
$183M
| $8M | 1.23% |
1,937,123
+966,023
|
|
||
|
PCSC
21
Perceptive Capital Solutions
PCSC
$118M
| $7.96M | 1.22% |
750,000
|
|
||
22
Amylyx Pharmaceuticals
AMLX
$1.58B
| $7.72M | 1.18% |
1,205,101
-266,486
|
|
||
|
23
CytomX Therapeutics
CTMX
$528M
| $6.99M | 1.07% |
3,081,414
+3,034,378
|
|
||
24
Taysha Gene Therapies
TSHA
$1.24B
| $6.95M | 1.07% |
3,009,870
+1,943,561
|
|
||
|
SAGE
25
DELISTED
Sage Therapeutics
SAGE
| $6.58M | 1.01% |
721,599
-20,896
|
|